Product Launch Excellence › New Market Entry
Different country. Different buying culture. Different regulatory environment. Different competitive landscape. Zero awareness, zero reference sites, zero advocates. The product is the same — everything else changes. New market entry in healthcare isn't a repeat of your launch playbook. It's a rebuild from first principles, in a market that doesn't yet know why it should care.
New Market Entry · 60s
47 product launches · 5 continents · Multi-market frameworks for global pharma · UK, Europe, Middle East, Americas, Asia-Pacific experience
You've hired a country manager or distributor. They have territory but no traction. Three months in, the pipeline is a list of people who took a business card at a conference and haven't returned a call.
You're using the same pitch that worked in your home market. It's not landing. The value proposition that resonated with UK surgeons doesn't resonate with German procurement committees or US hospital systems. Same product, different buying language.
No local reference sites. No local advocates. No local case studies. Every conversation starts from zero because nobody in this market has seen your product work in their context. You're asking clinicians to be the first, and nobody wants to be first.
Different compliance frameworks. Different claims requirements. Different approval pathways. Your home market materials can't be used. Everything needs rebuilding for local regulatory reality.
Most companies treat new market entry as a distribution problem: find the right partner, give them materials, wait for orders. But distribution without demand generation is just having your product available in a market where nobody's looking for it.
The real challenge isn't logistics. It's building credibility, relevance, and awareness in a market where you have none. That requires local messaging, local proof, local advocates, and a go-to-market strategy designed for the market you're entering — not adapted from the market you're leaving.
Five continents taught us this: what works in one market almost never translates directly to another. But the methodology for figuring out what works — that translates everywhere.
You can't export a playbook. You have to build one for each market.
Four phases. Each adapts to the local market; the methodology repeats. What we learn in month one shapes everything after.
01
Before anything else, we assess the market: competitive landscape, buying dynamics, regulatory environment, access pathways, and the specific barriers to adoption in this geography. Not assumptions from your home market — primary research in the market you're entering.
02
The 30-second pitch, the 2-minute story, the leave-behinds — all rebuilt for the local buying culture. The clinical value might be universal. The commercial language isn't. We build messaging that resonates with how this market actually buys.
03
No reference sites means no credibility. We design the first adopter strategy: how to identify, approach, and support your first local champions. KOL engagement. Early case study development. Advocacy programme design. The systematic approach to building the proof points this market needs to see.
Competitive landscape, buying dynamics, regulatory requirements, access pathways, barriers to adoption. The document that tells you what you're walking into.
Your product story, rebuilt for the local buying culture. 30-second, 2-minute, and 5-minute versions. Objection handling for local objections.
How to find, approach, and support your first local champions. KOL engagement plan. Reference site development roadmap. The credibility build, systematised.
What your local team says, how they say it, what they leave behind. Built for how this market buys. Not a translation of your home market playbook — a new build.
Website localisation, SEO for local search terms, content strategy for the new market, social presence. Being findable in the market you're entering.
Claims matrix built for local regulatory requirements. What you can say, what you can't, with evidence links. The foundation that lets your local team sell compliantly from day one.
Growing Companies
Problem
Complex product entering UK market. No local presence. No reference sites. Needed partnerships with major NHS trusts to establish credibility.
What we did
Market positioning. Messaging architecture for UK buyers. Sales enablement for local team. Stakeholder mapping across NHS trusts.
Result
Partnerships with King's College, St. George's, Nottingham, and Plymouth NHS Trusts. Local credibility established within 6 months.
Enterprise
Problem
Successful UK product. Entering Germany, France, and Benelux. Different buying cultures, different regulatory environments, different competitive landscapes. Same product, entirely different go-to-market requirements.
What we did
Market diagnostic per country. Local messaging architecture. Distributor enablement packs. Claims frameworks for each regulatory environment.
Result
First customers in all three markets within 9 months. Distributor enablement reduced onboarding from 6 months to 8 weeks.
Growing Companies
Problem
Proven product in European markets. Entering Middle East for the first time. No local network. Different procurement dynamics. Needed to build credibility with regional distributors and hospital groups.
What we did
Regional market assessment. Distributor identification and enablement. Local messaging. Event strategy for Arab Health congress.
Result
Distribution agreements signed within 4 months. First customers within 6 months. Sustainable pipeline through regional distributor network.
A new market hire costs £80-150K fully loaded. A distributor appointment takes 3-6 months to formalise. If they're selling without local messaging, local credibility, and a structured go-to-market plan, you're funding activity that looks productive but isn't converting.
Most failed market entries don't fail because the product doesn't work. They fail because the company exported a playbook that was designed for a different buying culture. By the time they realise, 12 months and £200K+ have been spent on a pipeline that doesn't exist.
The market entry framework costs less than one quarter of your country manager's salary. It's the difference between 12 months of activity and 12 months of traction.
By stage
First international market. Typically UK company entering Europe, or European company entering UK. Limited local resource. Need a complete go-to-market framework a small team can execute. Scope: market diagnostic, local messaging, first adopter strategy, sales playbook, digital market entry plan, event strategy. £15K-£40K / 3-6 months.
Multi-market expansion. Entering 2-5 markets simultaneously. Need consistent methodology with local adaptation. Distributor enablement across territories. Scope: multi-market diagnostic, global messaging framework with local adaptation, distributor enablement programme, claims frameworks per market, event portfolio strategy, attribution across markets. £40K-£100K+ / 6-12 months.
Can't we just translate our existing materials?
Translation isn't localisation. The words might translate, but the buying dynamics don't. A UK pitch that leads with clinical evidence might need to lead with health economics in Germany. We rebuild, not translate.
We already have a distributor in that market.
Good — that's distribution, not demand generation. Your distributor can place the product. They typically can't build the awareness, credibility, and demand that creates the orders. That's what we do.
How do you know our target market?
We've launched across 5 continents. We know the methodology for assessing any healthcare market — competitive landscape, buying dynamics, regulatory environment, access pathways. We learn your market fast because we know what questions to ask.
This feels like a big investment before we've proven the market.
It's a smaller investment than 12 months of a country manager with no pipeline. The market entry framework is designed to prove viability fast — first customers in 4-9 months, not 18.
We need someone on the ground in that market.
We can work alongside your local team or distributor. We don't replace boots on the ground — we give those boots a plan, the right messaging, and a credibility-building roadmap.
What if the market isn't viable?
The diagnostic tells you that in the first 4 weeks, before you've committed to the full programme. Better to know early than to discover at month 12 that the competitive landscape or regulatory environment makes entry uneconomic.
Strategic Lead
20 years in healthcare marketing across five continents. 47 product launches. Built market entry strategies for global pharma and growing companies entering new geographies. The cross-market experience that makes the diagnostic faster and the playbook more realistic.
Commercial Modelling
ACCA-qualified. Builds the financial models that justify market entry investment. Revenue projections, breakeven analysis, distributor economics. The numbers your board needs before approving the expansion.
30-minute triage call. No fee. No pitch. Bring your situation — we’ll tell you honestly whether we can help.
Healthcare innovations deserve recognition. We help them get it.
